Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (481-490 of 1,058) with videos related to

Pageof 106
Sort By:
Leukemia & Lymphoma|January 15, 2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaKami Maddocks, Erin Hertlein, Timothy L Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearanceJ C Byrd, J K Waselenko, T J Maneatis, et al.
Blood|October 31, 2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphomaKami Maddocks, Beth Christian, Samantha Jaglowski, et al.
Leukemia & Lymphoma|April 6, 2012
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Chempluschem|January 22, 2020
Bis(Nitroxymethylisoxazolyl) Furoxan: A Promising Standalone Melt-Castable ExplosiveEric C Johnson, Jesse J Sabatini, David E Chavez, et al.
Neurology|July 9, 2008
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraineS D Silberstein, L K Mannix, J Goldstein, et al.
International Journal of Cancer|February 24, 2015
Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemiaConstance Baer, Christopher C Oakes, Amy S Ruppert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicitySyed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.
Blood|October 11, 2014
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLJennifer A Woyach, Farrukh Awan, Ian W Flinn, et al.
Haematologica|July 30, 2016
Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)Christian Niederwieser, Deedra Nicolet, Andrew J Carroll, et al.
Pageof 106

Showing results (481-490 of 1,058) with videos related to

Sort By:
Pageof 106
Leukemia & Lymphoma|January 15, 2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaKami Maddocks, Erin Hertlein, Timothy L Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 1999
Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearanceJ C Byrd, J K Waselenko, T J Maneatis, et al.
Blood|October 31, 2014
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphomaKami Maddocks, Beth Christian, Samantha Jaglowski, et al.
Leukemia & Lymphoma|April 6, 2012
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaJohn C Byrd, Thomas J Kipps, Ian W Flinn, et al.
Chempluschem|January 22, 2020
Bis(Nitroxymethylisoxazolyl) Furoxan: A Promising Standalone Melt-Castable ExplosiveEric C Johnson, Jesse J Sabatini, David E Chavez, et al.
Neurology|July 9, 2008
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraineS D Silberstein, L K Mannix, J Goldstein, et al.
International Journal of Cancer|February 24, 2015
Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemiaConstance Baer, Christopher C Oakes, Amy S Ruppert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicitySyed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.
Blood|October 11, 2014
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLLJennifer A Woyach, Farrukh Awan, Ian W Flinn, et al.
Haematologica|July 30, 2016
Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance)Christian Niederwieser, Deedra Nicolet, Andrew J Carroll, et al.
Pageof 106